

Curriculum Vitae

Ekkehard Grünig Professor, Dr. med.

University Education

- 2017 Specialist Internal Medicine and Cardiology, Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany
- 2008 Professor, Head of Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany
- 1987-2004 Specialist Internal Medicine and Assistant Professor, Department of Medicine, Heidelberg, Germany
- 1984–1987 Approbation in Medicine, Department of Medicine, Mainz, Germany
- 1979–1984 Studies of Medicine and Philosophy, Department of Medicine, Giessen, Germany

Scientific Career

- 2018 Member of the “Risk Stratification and Medical Therapy of Pulmonary Arterial Hypertension” Task Force at the World Symposium on Pulmonary Hypertension in Nice
- 2014 Member of the “Genetics and Genomics” Task Force at the World Symposium on Pulmonary Hypertension in Nice
- 2012–2014 Spokesperson for the Pulmonary Hypertension Working Group of the German Society of Cardiology (DGK)
- 2012 Steering Committee member of the CompERA study

- 2010–2012 Co-spokesperson for the Pulmonary Hypertension Working Group of the German Society of Cardiology (DGK)
- 2010 Member of the German Task Force for the development of European guidelines for PH
- 2008 – 2010 Co-spokesperson of the Joint Working Group on PH of the Professional Societies for Cardiology, Pulmonology, and Pediatric Cardiology
- since 2006 Spokesperson of the PH-DACH Working Group of PH experts from Germany, Austria, and Switzerland
- from 2006 Steering Committee member of the European “Pulmotension” project
- 2004-2007 Ass. Prof. for Internal Medicine , Senior Physician, Faculty of medicine, University of Heidelberg, Germany
- since 2003 Treasurer of Working Group 25 (AG 25) on Pulmonary Hypertension of the German Society of Cardiology (DGK)
- since 2003 Board Member of the René Baumgart Foundation
- since 2003 Member of the Task Force for the development of guidelines for pulmonary hypertension
- 2003 Member of the Task Force at the World Congress on the Genetics of PAH, Italy
- since 1998 Member and Scientific Advisor of the *pulmonale hypertonie e.V.* patient organization
- 1990–2003 Internship, Consultant for Internal Medicine and Cardiology, University of Heidelberg, Germany
- 1988–1990 Doctoral candidate, Department of Cardiology, University of Heidelberg, Germany
- 1987 Approbation, State office for youth and social affairs Rheinland-Pfalz, Mainz, Germany
- 1984–1987 Research Fellow, Hospital for Children, University of Mainz, Germany

Citation Record

Total citations: 28,952; h-index:79; h-index since 2021: 59 (Google Scholar March 17th, 2026)

Selected Publications

Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Moles VM, Savale L, Vizza CD, Rosenkranz S, Shi Y, Miller B, Mackenzie HS, Kim SS, Loureiro MJ, Patel MJ, Koglin J, Cornell AG, Hoeper MM; **ZENITH Trial Investigators**. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. **N Engl J Med.** **2025;392(20):1987-2000**. doi: 10.1056/NEJMoa2415160.

Hoeper MM, Gomberg-Maitland M, Badesch DB, Gibbs JSR, **Grünig E**, Kopeć G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Manimaran S, Wang X, Miller B, Cornell AG, de Oliveira Pena J, Ghofrani HA, Humbert M. Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. **Eur Respir J.** **2025** May 6;65(5):2401424. doi: 10.1183/13993003.01424-2024.

Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin K. Efficacy and safety of macitentan/tadalafil single-tablet combination therapy in PAH: the A DUE randomized trial. **J Am Coll Cardiol.** **2024.** **30;83(4):473-484**. doi: 10.1016/j.jacc.2023.10.045.

Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, **Grünig E**, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. **N Engl J Med.** **2023;388(16):1478-1490**. doi: 10.1056/NEJMoa2213558.

Grünig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, Ulrich S, Saxer S, Bussotti M, Sommaruga M, Ghio S, Gumbiene L, Palevičiūtė E, Jurevičienė E, Cittadini A, Stanzola AA, Marra AM, Kovacs G, Olschewski H, Barberà JA, Blanco I, Spruit MA, Franssen FME, Vonk Noordegraaf A, Reis A, Santos M, Viamonte SG, Demeyer H, Delcroix M, Bossone E, Johnson M. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. **Eur Heart J.** **2021;42(23):2284-2295**. doi: 10.1093/eurheartj/ehaa696.

Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, Gorenflo M, Harutyunova S, Lorenz HM, Nagel C, Theobald V, Lichtblau M, Berlier C, Ulrich S, **Grünig E**, Benjamin N, Distler O. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. **Ann Rheum Dis.** **2020;79(3):370-378**. doi: 10.1136/annrheumdis-2019-216476.

Grünig E*, Eichstaedt C*, Barberà JA, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard L, Johnson M, Jurevičienė E, Kiely D, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock A. European Respiratory Society Task Force Statement on: Exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. **Eur Respir J.** **2019;53:1800332**. doi: 10.1183/13993003.00332-2018.

Ehken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, Uiker S, Halank M, Olsson K, Seeger W, Gall H, Rosenkranz S, Wilkens H, Mertens D, Seyfarth HJ, Opitz C, Ulrich S, Egenlauf B, **Grünig E**. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. **Eur Heart J.** **2016;37(1):35-44**. doi: 10.1093/eurheartj/ehv337.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoepfer MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; **GRIPHON Investigators**. Selexipag for the Treatment of Pulmonary Arterial Hypertension. **N Engl J Med.** 2015;**373(26):2522-33**. doi: 10.1056/NEJMoa1503184.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; **SERAPHIN Investigators**. Macitentan and morbidity and mortality in pulmonary arterial hypertension. **N Engl J Med.** 2013 Aug 29;**369(9):809-18**. doi: 10.1056/NEJMoa1213917

Ghofrani HA, D'Armini AM, Grimminger F, Hoepfer MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; **CHEST-1 Study Group**. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. **N Engl J Med.** 2013 Jul 25;**369(4):319-29**. doi: 10.1056/NEJMoa1209657.

Ghofrani HA, Galiè N, Grimminger F, **Grünig E**, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; **PATENT-1 Study Group**. Riociguat for the treatment of pulmonary arterial hypertension. **N Engl J Med.** 2013 Jul 25;**369(4):330-40**. doi: 10.1056/NEJMoa1209655.